$18.8 Billion is the total value of Baker Brothers Advisors's 99 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 23.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Seattle Genetics, Inc. | $5,719,544,000 | +33.8% | 50,057,277 | 0.0% | 30.41% | +4.6% | |
| INCY | Buy | Incyte Corporation | $2,792,221,000 | +17.6% | 31,976,873 | +0.0% | 14.84% | -8.1% |
| BGNE | BeiGene, Ltd.sponsored adr | $1,952,203,000 | +35.4% | 11,777,285 | 0.0% | 10.38% | +5.8% | |
| ACAD | ACADIA Pharmaceuticals Inc. | $1,747,759,000 | +18.9% | 40,854,586 | 0.0% | 9.29% | -7.1% | |
| ALXN | Alexion Pharmaceuticals, Inc. | $893,110,000 | +10.4% | 8,258,068 | 0.0% | 4.75% | -13.7% | |
| KOD | Buy | Kodiak Sciences Inc. | $794,852,000 | +504.4% | 11,047,289 | +20.8% | 4.23% | +372.2% |
| AMRN | Sell | Amarin Corporation plcsponsored adr | $739,609,000 | +17.4% | 34,496,685 | -17.0% | 3.93% | -8.2% |
| BMRN | BioMarin Pharmaceutical Inc. | $641,675,000 | +25.4% | 7,589,294 | 0.0% | 3.41% | -2.0% | |
| ASND | Ascendis Pharma A/Ssponsored adr | $471,654,000 | +44.4% | 3,390,270 | 0.0% | 2.51% | +12.9% | |
| EXAS | New | Exact Sciences Corporation | $239,134,000 | – | 2,585,791 | +100.0% | 1.27% | – |
| MRTX | Mirati Therapeutics, Inc. | $168,448,000 | +65.4% | 1,307,220 | 0.0% | 0.90% | +29.3% | |
| ARGX | argenx SEsponsored adr | $163,659,000 | +40.9% | 1,019,557 | 0.0% | 0.87% | +10.1% | |
| DBVT | Buy | DBV Technologies S.A.sponsored adr | $156,373,000 | +230.0% | 14,614,264 | +165.3% | 0.83% | +158.1% |
| NVTA | Buy | Invitae Corporation | $146,737,000 | -13.4% | 9,097,165 | +3.5% | 0.78% | -32.4% |
| HRTX | Heron Therapeutics, Inc. | $141,425,000 | +27.0% | 6,018,104 | 0.0% | 0.75% | -0.7% | |
| NBIX | Sell | Neurocrine Biosciences, Inc. | $134,819,000 | +5.7% | 1,254,243 | -11.4% | 0.72% | -17.4% |
| MYOK | Buy | MyoKardia, Inc. | $129,315,000 | +63.4% | 1,774,234 | +16.9% | 0.69% | +27.7% |
| IGMS | IGM Biosciences, Inc. | $119,975,000 | +115.0% | 3,144,000 | 0.0% | 0.64% | +67.9% | |
| MDGL | Madrigal Pharmaceuticals, Inc. | $106,533,000 | +5.7% | 1,169,278 | 0.0% | 0.57% | -17.5% | |
| RARX | Sell | Ra Pharmaceuticals, Inc. | $98,264,000 | +77.1% | 2,093,839 | -10.7% | 0.52% | +38.5% |
| PRNB | Buy | Principia Biopharma Inc. | $97,944,000 | +109.7% | 1,787,957 | +8.1% | 0.52% | +63.8% |
| AXSM | Buy | Axsome Therapeutics, Inc. | $85,764,000 | +448.7% | 829,757 | +7.4% | 0.46% | +330.2% |
| ZYME | Zymeworks Inc. | $77,667,000 | +83.3% | 1,708,472 | 0.0% | 0.41% | +43.4% | |
| TCDA | Tricida, Inc. | $74,344,000 | +22.3% | 1,969,905 | 0.0% | 0.40% | -4.6% | |
| RYTM | Rhythm Pharmaceuticals, Inc. | $62,180,000 | +6.3% | 2,708,200 | 0.0% | 0.33% | -16.8% | |
| INSM | Buy | Insmed Incorporated | $58,393,000 | +48.5% | 2,445,265 | +9.7% | 0.31% | +15.7% |
| KRYS | Krystal Biotech, Inc. | $57,300,000 | +59.5% | 1,034,674 | 0.0% | 0.30% | +25.0% | |
| BCEL | Atreca, Inc. | $54,652,000 | +26.4% | 3,532,760 | 0.0% | 0.29% | -1.0% | |
| BOLD | Sell | Audentes Therapeutics, Inc. | $48,154,000 | +13.8% | 804,720 | -46.6% | 0.26% | -11.1% |
| Neurocrine Biosciences, Inc.note 2.25% 5/15/2024 | $47,123,000 | +11.9% | 30,770,000 | 0.0% | 0.25% | -12.2% | ||
| CERS | Cerus Corporation | $45,365,000 | -18.1% | 10,749,937 | 0.0% | 0.24% | -36.1% | |
| NLTX | Sell | Neoleukin Therapeutics, Inc. | $41,860,000 | +29.9% | 3,397,740 | -69.9% | 0.22% | +1.8% |
| GWPH | GW Pharmaceuticals plcads | $38,776,000 | -9.1% | 370,845 | 0.0% | 0.21% | -29.0% | |
| BCRX | Sell | BioCryst Pharmaceuticals, Inc. | $37,764,000 | +3.6% | 10,946,166 | -14.0% | 0.20% | -19.0% |
| QURE | uniQure N.V. | $37,098,000 | +82.1% | 517,700 | 0.0% | 0.20% | +41.7% | |
| AUPH | New | Aurinia Pharmaceuticals Inc. | $34,481,000 | – | 1,701,929 | +100.0% | 0.18% | – |
| ADPT | Sell | Adaptive Biotechnologies Corporation | $33,373,000 | -7.3% | 1,115,411 | -4.3% | 0.18% | -27.8% |
| ALLK | Allakos Inc. | $32,393,000 | +21.3% | 339,690 | 0.0% | 0.17% | -5.5% | |
| ASMB | Buy | Assembly Biosciences, Inc. | $31,542,000 | +299.5% | 1,541,618 | +91.9% | 0.17% | +211.1% |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | $30,963,000 | +30.0% | 2,799,577 | 0.0% | 0.16% | +1.9% | |
| CCXI | Buy | ChemoCentryx, Inc. | $29,228,000 | +1981.8% | 739,016 | +257.0% | 0.16% | +1450.0% |
| MRUS | Buy | Merus N.V. | $28,688,000 | +38.8% | 2,037,469 | +75.6% | 0.15% | +8.5% |
| URGN | Buy | UroGen Pharma Ltd. | $27,747,000 | +55.7% | 831,488 | +11.2% | 0.15% | +22.3% |
| AIMT | Aimmune Therapeutics, Inc. | $22,556,000 | +59.8% | 673,908 | 0.0% | 0.12% | +25.0% | |
| FREQ | New | Frequency Therapeutics, Inc. | $21,587,000 | – | 1,231,433 | +100.0% | 0.12% | – |
| ALKS | Buy | Alkermes plc | $16,180,000 | +32.7% | 793,130 | +26.9% | 0.09% | +3.6% |
| BioMarin Pharmaceutical Inc.note 0.599% 8/1/2024 | $15,841,000 | +7.6% | 15,000,000 | 0.0% | 0.08% | -16.0% | ||
| UROV | New | Urovant Sciences Ltd. | $15,510,000 | – | 1,000,000 | +100.0% | 0.08% | – |
| APLS | Buy | Apellis Pharmaceuticals, Inc. | $15,217,000 | +101.3% | 496,969 | +58.4% | 0.08% | +58.8% |
| XNCR | Xencor, Inc. | $14,723,000 | +2.0% | 428,120 | 0.0% | 0.08% | -20.4% | |
| AGLE | Aeglea BioTherapeutics, Inc. | $13,092,000 | -0.7% | 1,713,604 | 0.0% | 0.07% | -22.2% | |
| HOOK | HOOKIPA Pharma Inc. | $10,920,000 | +63.1% | 892,857 | 0.0% | 0.06% | +26.1% | |
| CABA | New | Cabaletta Bio, Inc. | $8,890,000 | – | 636,363 | +100.0% | 0.05% | – |
| IDRA | Idera Pharmaceuticals, Inc. | $8,388,000 | -37.0% | 4,608,786 | 0.0% | 0.04% | -50.5% | |
| NXTC | NextCure, Inc. | $8,450,000 | +82.6% | 150,000 | 0.0% | 0.04% | +45.2% | |
| RETA | New | Reata Pharmaceuticals, Inc.cl a | $8,378,000 | – | 40,983 | +100.0% | 0.04% | – |
| SGMO | Sangamo Therapeutics, Inc. | $8,369,000 | -7.5% | 999,823 | 0.0% | 0.04% | -29.0% | |
| PTGX | Protagonist Therapeutics, Inc. | $8,279,000 | -41.3% | 1,174,282 | 0.0% | 0.04% | -54.2% | |
| MIRM | Mirum Pharmaceuticals, Inc. | $8,173,000 | +143.8% | 333,333 | 0.0% | 0.04% | +87.0% | |
| ABEO | Buy | Abeona Therapeutics Inc. | $7,483,000 | +157.1% | 2,288,235 | +77.6% | 0.04% | +100.0% |
| FLGT | Buy | Fulgent Genetics, Inc. | $7,346,000 | +465.5% | 569,444 | +355.6% | 0.04% | +333.3% |
| IFRX | Inflarx N.V. | $7,043,000 | +60.3% | 1,778,415 | 0.0% | 0.04% | +23.3% | |
| ALBO | Albireo Pharma, Inc. | $6,355,000 | +27.1% | 250,000 | 0.0% | 0.03% | 0.0% | |
| CNST | Constellation Pharmaceuticals, Inc. | $6,281,000 | +629.5% | 133,333 | 0.0% | 0.03% | +450.0% | |
| MTNB | Buy | Matinas BioPharma Holdings, Inc. | $5,975,000 | +377.2% | 2,632,348 | +32.6% | 0.03% | +255.6% |
| ARAV | Sell | Aravive, Inc. | $5,924,000 | +18.9% | 433,333 | -34.7% | 0.03% | -8.8% |
| ORTX | Orchard Therapeutics plcads | $5,578,000 | +15.7% | 405,702 | 0.0% | 0.03% | -9.1% | |
| MLND | New | Millendo Therapeutics, Inc. | $5,617,000 | – | 833,333 | +100.0% | 0.03% | – |
| CPRX | Catalyst Pharmaceuticals, Inc. | $5,032,000 | -29.4% | 1,341,902 | 0.0% | 0.03% | -43.8% | |
| NGM | NGM Biopharmaceuticals, Inc. | $4,623,000 | +33.5% | 250,000 | 0.0% | 0.02% | +4.2% | |
| SYRS | Sell | Syros Pharmaceuticals, Inc. | $4,769,000 | -52.9% | 690,167 | -29.2% | 0.02% | -63.8% |
| EVFM | Buy | Evofem Biosciences, Inc. | $4,670,000 | +808.6% | 756,813 | +641.6% | 0.02% | +733.3% |
| MTEM | Buy | Molecular Templates, Inc. | $4,429,000 | +164.4% | 316,730 | +24.6% | 0.02% | +118.2% |
| MRKR | Marker Therapeutics, Inc. | $4,320,000 | -43.6% | 1,500,000 | 0.0% | 0.02% | -55.8% | |
| CRNX | Crinetics Pharmaceuticals, Inc. | $4,391,000 | +66.8% | 175,000 | 0.0% | 0.02% | +27.8% | |
| YMAB | Buy | Y-mAbs Therapeutics, Inc. | $4,329,000 | +61.6% | 138,514 | +34.7% | 0.02% | +27.8% |
| BLUE | bluebird bio, Inc. | $3,510,000 | -4.4% | 40,000 | 0.0% | 0.02% | -24.0% | |
| VKTX | Viking Therapeutics, Inc. | $3,409,000 | +16.6% | 425,000 | 0.0% | 0.02% | -10.0% | |
| BLCM | Bellicum Pharmaceuticals, Inc. | $3,454,000 | +22.8% | 2,677,818 | 0.0% | 0.02% | -5.3% | |
| GTHX | G1 Therapeutics, Inc. | $3,363,000 | +16.0% | 127,236 | 0.0% | 0.02% | -10.0% | |
| HARP | Harpoon Therapeutics, Inc. | $3,169,000 | +8.3% | 214,285 | 0.0% | 0.02% | -15.0% | |
| MNLO | Menlo Therapeutics Inc. | $3,248,000 | +3.6% | 700,000 | 0.0% | 0.02% | -19.0% | |
| GLPG | Sell | Galapagos NVsponsored adr | $2,704,000 | -29.3% | 13,072 | -47.9% | 0.01% | -46.2% |
| AUTL | Autolus Therapeutics plcsponsored ads | $2,069,000 | +6.3% | 156,773 | 0.0% | 0.01% | -15.4% | |
| ANAB | AnaptysBio, Inc. | $1,838,000 | -53.6% | 113,086 | 0.0% | 0.01% | -63.0% | |
| NTLA | Intellia Therapeutics, Inc. | $1,886,000 | +9.9% | 128,538 | 0.0% | 0.01% | -16.7% | |
| CTMX | CytomX Therapeutics, Inc. | $1,615,000 | +12.5% | 194,377 | 0.0% | 0.01% | -10.0% | |
| IDYA | IDEAYA Biosciences, Inc. | $1,500,000 | -16.7% | 200,000 | 0.0% | 0.01% | -33.3% | |
| GLMD | Galmed Pharmaceuticals Ltd. | $1,246,000 | +20.9% | 215,594 | 0.0% | 0.01% | 0.0% | |
| RCUS | Arcus Biosciences, Inc. | $1,227,000 | +10.9% | 121,534 | 0.0% | 0.01% | -12.5% | |
| ISEE | New | IVERIC bio, Inc. | $1,216,000 | – | 141,750 | +100.0% | 0.01% | – |
| Buy | Trillium Therapeutics Inc. | $1,133,000 | +631.0% | 1,100,000 | +117.7% | 0.01% | +500.0% | |
| LPTX | Leap Therapeutics, Inc. | $1,096,000 | -4.3% | 978,454 | 0.0% | 0.01% | -25.0% | |
| SBPH | Spring Bank Pharmaceuticals, Inc. | $969,000 | -54.1% | 613,144 | 0.0% | 0.01% | -64.3% | |
| ADMS | Adamas Pharmaceuticals, Inc. | $654,000 | -25.9% | 172,630 | 0.0% | 0.00% | -50.0% | |
| INFI | Infinity Pharmaceuticals, Inc. | $557,000 | -6.9% | 580,400 | 0.0% | 0.00% | -25.0% | |
| AFMD | Affimed N.V. | $548,000 | -6.8% | 200,000 | 0.0% | 0.00% | -25.0% | |
| DVAX | Dynavax Technologies Corporation | $429,000 | +60.1% | 75,000 | 0.0% | 0.00% | 0.0% | |
| SNSS | Sunesis Pharmaceuticals, Inc. | $188,000 | -53.1% | 556,665 | 0.0% | 0.00% | -66.7% | |
| RTTR | Exit | Ritter Pharmaceuticals, Inc. | $0 | – | -279,999 | -100.0% | -0.00% | – |
| AQST | Exit | Aquestive Therapeutics, Inc. | $0 | – | -99,600 | -100.0% | -0.00% | – |
| SRRA | Exit | Sierra Oncology, Inc. | $0 | – | -2,000,000 | -100.0% | -0.01% | – |
| FOMX | Exit | Foamix Pharmaceuticals Ltd. | $0 | – | -498,189 | -100.0% | -0.01% | – |
| FTSV | Exit | Forty Seven, Inc. | $0 | – | -250,000 | -100.0% | -0.01% | – |
| CYCN | Exit | Cyclerion Therapeutics, Inc. | $0 | – | -202,581 | -100.0% | -0.02% | – |
| DOVA | Exit | Dova Pharmaceuticals, Inc. | $0 | – | -102,205 | -100.0% | -0.02% | – |
| XLRN | Exit | Acceleron Pharma Inc. | $0 | – | -83,900 | -100.0% | -0.02% | – |
| ACHN | Exit | Achillion Pharmaceuticals, Inc. | $0 | – | -1,095,359 | -100.0% | -0.03% | – |
| HALO | Exit | Halozyme Therapeutics, Inc. | $0 | – | -299,969 | -100.0% | -0.03% | – |
| MIST | Exit | Milestone Pharmaceuticals Inc. | $0 | – | -266,667 | -100.0% | -0.03% | – |
| XBIT | Exit | Xbiotech Inc. | $0 | – | -521,327 | -100.0% | -0.04% | – |
| DERM | Exit | Dermira, Inc. | $0 | – | -906,943 | -100.0% | -0.04% | – |
| ACOR | Exit | Acorda Therapeutics, Inc. | $0 | – | -2,232,589 | -100.0% | -0.04% | – |
| LJPC | Exit | La Jolla Pharmaceutical Company | $0 | – | -1,559,231 | -100.0% | -0.09% | – |
| CBAY | Exit | CymaBay Therapeutics, Inc. | $0 | – | -5,707,411 | -100.0% | -0.20% | – |
| ONCE | Exit | Spark Therapeutics, Inc. | $0 | – | -751,927 | -100.0% | -0.50% | – |
| GHDX | Exit | Genomic Health, Inc. | $0 | – | -9,244,665 | -100.0% | -4.26% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.